Publications Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set Citation Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018 May;16(5):637-647.e13. doi: 10.1016/j.cgh.2017.08.025. Epub 2017 Aug 24. PMID: 28843356. Abstract Background & aims: Advances in development of therapeutic agents for ulcerative colitis (UC) have been paralleled by innovations in trial design. It would be useful to identify a core outcome set, to standardize outcome definitions for efficacy and safety in clinical trials. We performed a systematic review of efficacy and safety outcomes reported in placebo-controlled randomized controlled trials of patients with UC. Tags Adverse Effects, COS, Gastrointestinal Agents, IBD, MCS, Pathology, RCT, therapeutic use, Therapy, Treatment Outcome, UCDAI, Ulcerative Colitis Read More
